The episode opens with a phrase that tells you exactly where 2026 is at. Dr. Abud Bakri, the internal-medicine doctor sitting across from Andrew Huberman, describes what he calls “the celebrity protocol”: people stacking a GLP-1 drug for appetite, a growth-hormone peptide for muscle, and a hormone modulator on top, all at once. “You’re seeing people lose a lot of fat, gain a lot of muscle in short amounts of time,” he says. “Is that healthy? We’ll find out.”
We’ll find out. That’s the honest subtitle of the entire three hours. Bakri runs an actual peptide practice, so this wasn’t a wellness influencer reading off a supplement label. It was a doctor who prescribes this stuff talking, on the record, about how thin the ground is under most of it. Below is what was actually said, the parts worth arguing with, and where the science holds up or doesn’t.
A quick note on the quotes: Huberman’s official transcript isn’t out yet, so these are pulled from the episode’s broadcast captions. The wording is faithful; I’ve cleaned up the odd garbled name. Everything in quotation marks was said on the show.
The Line That Runs Through Everything: “All the animal data come from one group”
Early on, Huberman says the quiet part out loud about BPC-157, the episode’s main character: “All the animal data come from one group.” Bakri doesn’t dodge it. “Almost all of it,” he agrees. “There’s a couple of Chinese groups that have also replicated some of their work.”
Sit with that. The most hyped recovery peptide on the internet rests almost entirely on the output of a single research lab in Croatia (the Sikiric group), with a thin layer of partial replication behind it. That’s not nothing, plenty of real science starts in one lab, but it’s a long way from the settled, independently-confirmed picture the marketing implies.
Fact check: true, and it matters. If you actually dig through the BPC-157 literature, the Zagreb group’s fingerprints are on the overwhelming majority of it. Independent replication is the thing science uses to catch flukes, bias, and wishful thinking, and BPC-157 just doesn’t have much of it yet. This single fact should reframe how you read every exciting BPC-157 claim you see online.
BPC-157: The Stuff Is Genuinely Interesting, the Evidence Is Genuinely Thin
BPC-157 ate up roughly fifty minutes, which tells you where the real curiosity is. First, a myth Bakri kills immediately: “We don’t naturally make BPC-157. That’s what you’ll commonly hear online.” The body makes a larger gastric-juice protein; BPC-157 is a synthetic fragment of it. The “it’s just something your body already produces” line you’ll see on vendor pages is, strictly speaking, wrong.
The origin story is better than the marketing. It traces back through Pavlov’s work on gastric juice, to Hans Selye’s classic stress experiments (stressed animals showed enlarged adrenals, wrecked stomach lining, and a shrunken thymus), and finally to the Croatian group that isolated the fragment. Bakri’s genuinely interesting take: everyone fixates on the tendon-and-joint stuff, “but the neuro” side is where it gets strange. He describes animal studies where they got mice dependent on alcohol and then forced withdrawal, which can be lethal, and the animals given BPC didn’t crash the way they should have. Huberman jumps in fast: “We did not just recommend you take BPC with alcohol.” It’s a funny moment that also flags how far the animal research wanders from anything a human should try at home.
Here’s the part that should stop you cold, and it’s the best moment in the episode.
The dosing chasm nobody talks about
What’s the actual human evidence for BPC-157? Two very small Phase 1/2 trials from the early 2000s, from that same Croatian group, using rectal enemas for a gut-inflammation condition, at doses “up to like 80 milligrams.” Now compare that to how people actually take it. “Most people are injecting micrograms,” Bakri notes, “100 or 200 micrograms per day.”
Do the math: the only human trials used doses roughly 400 to 800 times higher than what biohackers inject, by a completely different route, for a completely different purpose. When Huberman asks Bakri what dose he’s personally used, Bakri admits it wasn’t micrograms, “you were up in the grams”, and says he suspects “the problem” with people who see nothing is that the typical low dose does nothing at all.
My take: this is the most useful sixty seconds of the whole episode, and almost no one selling BPC-157 will ever mention it. The human safety and efficacy data, such as it is, exists at a dose and route that has nothing to do with the subcutaneous microgram shots people actually do. Anyone who tells you the “standard protocol” is well-supported is, at best, guessing. The honest position is that the effective dose in humans is genuinely unknown.
The safety flag: angiogenesis
The recurring worry Bakri keeps circling is that BPC-157 appears to drive angiogenesis, the growth of new blood vessels, partly through the VEGF pathway. Huberman shares a sharp anecdote: a physician friend who likes BPC told him that when he runs it for a joint, the small spiderweb angiomas on his face get worse. “It makes sense though if it’s promoting angio[genesis],” Huberman says. Bakri adds that on Reddit “you’ll find signals of hematomas getting worse, which makes sense with the VEGF pathway.”
Fact check: real mechanism, unproven conclusion. BPC-157’s effect on VEGF is documented in the animal literature, but it’s not a simple “more blood vessels” story; studies show it can push VEGF up or down depending on context. The leap people make from there (“so it must feed tumor-growth”) is mechanistically plausible and worth taking seriously, but it has not been demonstrated in living humans. Take it as a real reason for caution, not a proven danger. If you want the deeper, sourced version of how BPC-157 compares to its usual partner, we wrote BPC-157 vs TB-500.
The Rename Trick: How BPC-157 Became “Pentadeca Arginate”
This was the most quietly damning ten minutes, because it’s about marketing, not biology. In late 2023, U.S. regulators effectively told compounding pharmacies to stop making BPC-157. The industry’s response was not to stop. It was to rebrand.
You’ll now see the identical active sequence sold as “Pentadeca Arginate,” or PDA, technically the arginate-salt form, with a fresh name that wasn’t on the original list. Same molecule, new label, and suddenly a “vibrant” market of oral PDA capsules and “research only” vials appears in the gray zone. It’s regulatory whack-a-mole, and it tells you something true about this whole category: the name on the bottle is often a marketing decision, not a chemical one. TB-500, BPC’s classic “Wolverine stack” partner (and available as the Wolverine Blend), lives in the same no-clear-receptor, lots-of-hype, little-human-data neighborhood.
GLP-1s and Retatrutide: The Only Compounds Here With Real Human Weight Behind Them
When the conversation turns to the weight drugs, the evidence base suddenly gets serious. Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound) are peptides too, most people don’t realize the appetite blockbusters and the gym-bro recovery vials are chemically cousins.
Huberman raises a fascinating point, crediting neuroscientist Zach Knight: the old diabetic-dose drugs nudged GLP-1 signaling up maybe two-to-fourfold, and the weight effects weren’t dramatic. The new drugs, and especially Retatrutide, are, in his words, “thousandfold increases,” and “we don’t know what the long-term effects of those are on like neuroplasticity and learning.” Bakri’s response is refreshingly even-handed: “Could be positive. We shouldn’t always assume those effects are bad.”
Fact check: the spirit is right, the number is loose. “Thousandfold” is doing a lot of work there and is almost certainly a rhetorical exaggeration rather than a measured pharmacodynamic ratio, real-world receptor-level multiples for these drugs are debated and depend heavily on what you’re measuring. The underlying point stands, though: we are flooding an ancient signaling system far past anything evolution tuned it for, and the long-term brain effects are genuinely unknown. On the hopeful side, Bakri notes an Alzheimer’s-prevention trial “last year didn’t show a good signal,” but argues that controlling insulin dynamics could still turn out to matter for the brain. We did the full, sober breakdown of the trial numbers in peptides for weight loss.
The Story That Should Scare You Off Sketchy Vendors
The single most memorable anecdote in three hours: a patient insisted to Bakri that something was off with his “retatrutide.” He’d started tanning. He wasn’t injecting retatrutide at all, he was injecting melanotan, the tanning peptide, because the gray-market supplier was funneling different raw materials into the same unlabeled “stringency bins.” Same vial, same label, completely different molecule.
That’s the whole problem with this category in one story. The danger usually isn’t the compound you researched, it’s that the vial might contain something else entirely, or be underdosed, or be contaminated. You cannot reason about a dose when you don’t know what’s in the bottle. This is exactly why every compound we carry ships with third-party Janoshik lab testing: purity, identity, sterility, the real numbers, posted. Not as a marketing flourish, as the one variable that separates research material from a mystery liquid.
The Weird Frontier: Epitalon, Pinealon, and the Soviet Bioregulators
Then it gets strange in a fun way. Epitalon and Pinealon come out of Soviet-era “peptide bioregulator” research (the Khavinson lineage), tied to the pineal gland and pitched for sleep, cognition, and aging. The dosing is tiny, Bakri says the literature runs “from 10 to 100 micrograms.” Then comes the detail that earns the section: the original sourcing was desiccated animal brain tissue. “10 milligrams of desiccated cow brain might give you a few hundred micrograms of pinealon,” he says, which prompts Huberman to make the obvious mad-cow-prion joke.
Huberman also brings welcome skepticism to the premise itself. He recounts asking the renowned neuroanatomist Harvey Karten whether the classic “your pineal gland calcifies as you age” story is even real, and Karten “kind of brushed it aside.”
Fact check: the foundation is shakier than the supplement market implies. Pineal calcification does show up on aging brain scans, but its functional significance, and the idea that a peptide reverses it to do anything useful, is unproven. The bioregulator research is intriguing and almost entirely from one national research tradition with limited independent Western replication. File it under “genuinely interesting, deeply unsettled.”
The Quick Hits
Thymosin Alpha-1 came across as the most clinically grounded of the bunch, part of a family of thymic hormones, studied seriously in immune research rather than just in mice. If you want one compound from this episode that isn’t running on fumes and a single lab, this is it.
GHK-Cu got a nice origin beat: researcher Loren Pickart identified this copper-binding tripeptide in collagen tissue and proposed it as a control switch for collagen synthesis and breakdown. It’s the most mainstream compound here, it’s already sitting in skincare serums, and the episode tied it to topical use and red-light therapy.
Growth-hormone secretagogues like CJC-1295 and Ipamorelin came up around “somatopause,” the age-related decline in growth-hormone output. Bakri’s caution here is the one to remember: anything that pushes IGF-1 back up carries a real theoretical tradeoff, because elevated IGF-1 is epidemiologically linked to abnormal-tissue-growth risk. Fact check: that IGF-1 association is real in population data, but whether nudging it with peptides actually changes an individual’s risk is unestablished, a genuine open question, not a settled danger. Our peptides for muscle growth guide covers this family in depth.
So, Was It Worth Three Hours?
Honestly, parts of it were excellent, and not for the reasons the algorithm wants. The valuable thread wasn’t “here’s what to take.” It was a practicing doctor repeatedly undercutting the hype: the data’s from one lab, the human dose is unknown, the safety signals are real-but-unproven, and the supply chain is a mess.
If you take one thing from the episode, make it this: the interesting biology is real, the human evidence is thinner than your feed suggests, and the gap between the two is filled almost entirely with marketing. The smartest question in this whole space isn’t “which peptide?” It’s “do I actually know what’s in this vial, and at what dose?” Bakri, who prescribes these things for a living, basically spent three hours making that exact case.
Worth the marathon if you’ve got it. If not, that’s what this was for.
This article recaps a public Huberman Lab podcast episode for educational and informational purposes, quoting the hosts’ own statements. Compounds discussed are described in the context of published research and the episode’s discussion. All Peptigo products are sold strictly for laboratory and research use only, not for human or veterinary use, and nothing here is medical advice. Peptigo does not make medical claims. Consult a qualified professional before any decision involving these compounds.
Episode: “Peptides: The Science, Uses & Safety” with Dr. Abud Bakri, Huberman Lab, June 1, 2026. Quotes transcribed from the episode broadcast.